[6-K] NOVO NORDISK A S Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over a 12‑month period beginning 4 February 2026.

Under the current tranche, Novo Nordisk targets up to DKK 3.8 billion of B share repurchases between 4 February 2026 and 4 May 2026. As of 17 April 2026, it has repurchased 12,257,992 B shares at an average price of DKK 256.87, for a total of DKK 3,148,710,807. Following these transactions, Novo Nordisk holds 28,397,791 B shares as treasury shares, representing 0.6% of its 4,465,000,000 total A and B shares outstanding.

Key Figures

Total buyback programme size: DKK 15 billion Current tranche size: DKK 3.8 billion Shares repurchased to 17 April 2026: 12,257,992 B shares +5 more

8 metrics

Total buyback programme size DKK 15 billion Planned B share repurchases over 12 months from 4 February 2026

Current tranche size DKK 3.8 billion B share repurchases from 4 February 2026 to 4 May 2026

Shares repurchased to 17 April 2026 12,257,992 B shares Cumulative repurchases since 4 February 2026

Cumulative transaction value DKK 3,148,710,807 Value of B shares repurchased as of 17 April 2026

Average repurchase price DKK 256.87 per B share Average price for shares repurchased since 4 February 2026

Treasury B shares held 28,397,791 B shares Treasury position after reported transactions, equal to 0.6% of capital

Total share capital 4,465,000,000 A and B shares Total number of shares including treasury shares

Employees worldwide About 68,800 Global workforce across 80 countries

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, Article 5 of Regulation No 596/2014, +2 more

6 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 28,397,791 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"in accordance with ... (the "Safe Harbour Rules")"

Article 5 of Regulation No 596/2014 regulatory

"in accordance with Article 5 of Regulation No 596/2014 of the European Parliament"

Commission Delegated Regulation (EU) 2016/1052 regulatory

"and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016"

ADRs financial

"Its ADRs are listed on the New York Stock Exchange (NVO)."

American Depositary Receipts (ADRs) are certificates issued by a U.S. bank that stand in for shares of a foreign company, allowing those shares to be bought and sold on U.S. stock exchanges in U.S. dollars. Think of an ADR as a local ticket representing a foreign stock: it makes trading, settlement, and tax reporting simpler for U.S. investors, but still exposes them to risks like currency moves, different accounting rules, and foreign corporate practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 04/20/2026 - 09:38 AM Learn about SEC filing dates

FAQ

What share repurchase programme did Novo Nordisk (NVO) outline in this report?

Novo Nordisk plans to repurchase up to DKK 15 billion of B shares over a 12‑month period starting 4 February 2026. This broad programme is conducted under EU Safe Harbour Rules to manage capital structure and return cash to shareholders.

How much stock has Novo Nordisk (NVO) repurchased so far in 2026?

As of 17 April 2026, Novo Nordisk has repurchased 12,257,992 B shares since 4 February 2026. The average purchase price was DKK 256.87 per B share, for a total transaction value of DKK 3,148,710,807 under the current programme tranche.

What is the size and period of Novo Nordisk’s current share buyback tranche?

Under the tranche initiated 4 February 2026, Novo Nordisk plans to repurchase B shares for up to DKK 3.8 billion. This specific tranche runs from 4 February 2026 to 4 May 2026, as part of the larger DKK 15 billion programme.

How many treasury shares does Novo Nordisk (NVO) now hold?

After the reported transactions, Novo Nordisk holds 28,397,791 B shares of DKK 0.10 as treasury shares. This position represents about 0.6% of the company’s total 4,465,000,000 A and B shares, including treasury shares, in its share capital.

On which exchanges are Novo Nordisk’s shares and ADRs listed?

Novo Nordisk’s B shares trade on Nasdaq Copenhagen under the symbol Novo-B. Its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the ticker NVO, providing access for investors in U.S. markets.

What business does Novo Nordisk (NVO) focus on according to this filing?

Novo Nordisk is described as a leading global healthcare company focused on serious chronic diseases, building on its heritage in diabetes. It employs about 68,800 people in 80 countries and markets products in around 170 countries worldwide.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

April 20, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 13 April 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	11,007,992		2,835,176,799
13 April 2026	260,000	237.12	61,650,199
14 April 2026	260,000	246.63	64,124,056
15 April 2026	250,000	253.43	63,358,536
16 April 2026	240,000	259.91	62,378,913
17 April 2026	240,000	258.43	62,022,304
Accumulated under the programme	12,257,992		3,148,710,807

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 28,397,791 B shares of DKK 0.10 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12month period beginning 4 February 2026. As of 17 April 2026, Novo Nordisk has since 4 February 2026 repurchased a total 12,257,992 B shares at an average share price of DKK 256.87 per B share equal to a transaction value of DKK 3,148,710,807.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Alex Bruce +45 34 44 26 13 axeu@novonordisk.com	Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 27 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 20, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer